Novo Nordisk Files For Speedier Version Of NovoLog
Faster-acting formulation of insulin aspart represents an incremental advance over company’s flagship mealtime insulin NovoLog/NovoRapid, which is losing patent protection in the US.
Faster-acting formulation of insulin aspart represents an incremental advance over company’s flagship mealtime insulin NovoLog/NovoRapid, which is losing patent protection in the US.